Science, Policy, and Saving Lives
Exploring the science, policy, and real-world implementation of drug checking as a critical harm reduction strategy in the overdose crisis.
In an unmarked van parked near a music festival, a public health worker carefully places a tiny scoop of a powder into a vial. At a storefront harm reduction center in Victoria, Canada, a technician analyzes a sample submitted by a community member. In a laboratory at the U.S. National Institute of Standards and Technology (NIST), a scientist develops a new method to extract minute drug residues from a used test strip. These are all scenes from the front lines of drug checking, a rapidly evolving harm reduction strategy that is saving lives in the midst of a devastating overdose crisis.
The practice is simple in concept but profound in impact: allow people to test their drugs to see what's really in them. The goal is not to encourage use, but to provide the information necessary for informed consumption and risk reduction in an illicit drug market that has become increasingly unpredictable and dangerous. This article delves into the science, policy, and real-world implementation of drug checking, exploring how this critical tool is reshaping our response to one of today's most pressing public health challenges.
Identifying substances in the drug supply
Protecting people from dangerous substances
Monitoring trends in the drug market
The contemporary drug supply is no longer simply comprised of discrete substances like heroin or cocaine. Instead, it has become a complex, ever-changing mixture of potent synthetic compounds. Fentanyl and its analogues remain the primary drivers of the overdose crisis, involved in over 75% of overdose deaths in the U.S. 6 . However, the situation is becoming even more complicated with the emergence of other substances.
Recent data from drug checking services in Canada reveals a startling picture of this polysubstance market. In June and July 2025, approximately 36-42% of expected opioid samples contained benzodiazepines like bromazolam 3 5 . This combination is particularly dangerous because while naloxone can reverse opioid overdose, it does nothing to counter the respiratory depression caused by benzodiazepines. Meanwhile, veterinary sedatives like xylazine and the even more potent medetomidine have also emerged as significant adulterants in the opioid supply 4 5 .
| Substance Category | Purity/Composition Findings | Key Adulterants Detected | Frequency of Adulteration |
|---|---|---|---|
| Opioids ("Down") | Median fentanyl concentration: 7.2-8.1% 3 5 | Benzodiazepines (bromazolam), Medetomidine, Xylazine | 41.5% contained benzodiazepines (July 2025) 5 |
| Stimulants | 94-95% of cocaine samples were as expected 3 5 | Occasionally contained levamisole, phenacetin | Low in direct testing, but DEA reports 1 in 4 cocaine submissions contain fentanyl 4 |
| MDMA/MDA | 90-91% as expected 3 5 | Occasionally contained other amphetamines, ketamine, or novel stimulants | Approximately 9-10% contained unexpected substances 3 5 |
| Benzodiazepines | Various forms (pills, powders) | Frequent misrepresentation in pressed pills | 36-38% of expected benzodiazepine samples came as pressed pills 3 5 |
Drug checking employs a multi-technique approach, balancing speed, accuracy, and cost. Services often use a combination of methods to provide the most comprehensive analysis possible.
Quick detection of specific drug classes like fentanyl. Ideal for point-of-care use with immediate results.
Limitations: Compound-specific, don't reveal concentration or other substances 9
Identification of chemical components based on molecular vibrations. Relatively quick results for direct service provision.
Limitations: Limited sensitivity for low-concentration adulterants
Highly sensitive identification and quantification of substances. The gold standard for laboratory analysis.
Limitations: Lengthy turnaround times, requires specialized equipment and expertise 9
Direct Analysis in Real Time Mass Spectrometry offers rapid chemical analysis with minimal sample preparation.
Limitations: Expensive equipment, requires technical expertise 9
A crucial challenge in drug checking is bridging the gap between rapid, on-site testing and comprehensive laboratory analysis. In 2025, researchers at NIST developed and published an innovative method to address this very problem 9 .
Researchers tested different approaches to determine the most effective way to recover compounds from used test strips. They evaluated various solvents and agitation methods.
They assessed whether the extracts could be successfully analyzed using Direct Analysis in Real Time Mass Spectrometry (DART-MS), a rapid and sensitive analytical technique.
The team established the limits of detection for a range of analytes to understand how little of a substance could still be identified after the extraction process.
Finally, the method was tested using used test strips actually submitted by harm reduction sites to evaluate its performance with real-world samples.
The optimized protocol that emerged was remarkably straightforward: a test strip is cut, then extracted with 0.5 milliliters of methanol while vortexing (mixing) for just 10 seconds 9 . This simple process proved highly effective at recovering sufficient drug material for additional analysis.
The NIST experiment yielded promising results with significant implications for the field. DART-MS successfully identified compounds of interest from the test strip extracts, and the background chemicals from the test strips themselves were characterized and found not to interfere significantly with analysis 9 .
Most impressively, the method demonstrated high concordance (96% agreement) between the initial test strip results and the analysis of the extracts. Furthermore, there was approximately 80% agreement in compound identification between the used test strip extracts and actual drug samples, regardless of test strip type or preparation method 9 .
This research is significant because it creates a low-barrier pathway to high-quality drug market data. Instead of relying on drug users to submit separate samples for laboratory testing—which they may be reluctant to do—services can now perform rapid testing with strips and then send those same used strips to a lab for comprehensive analysis. This generates invaluable data on emerging drug threats without requiring additional effort from service users. As the drug supply evolves with new synthetic opioids like nitazenes and novel benzodiazepines, such innovative surveillance methods become increasingly crucial for public health response 2 5 .
While the science of drug checking continues to advance, its implementation faces significant policy barriers and political challenges. In the United States, a complex patchwork of federal and state regulations often limits the reach of these life-saving services 6 .
Federal policies in the U.S. present several obstacles to comprehensive drug checking implementation. The Controlled Substances Act effectively limits the operation of overdose prevention centers, and drug paraphernalia laws in many states criminalize the possession of items used to test or consume drugs 6 . Additionally, the use of federal funds for purchasing syringes and certain drug checking equipment is often restricted 6 .
"access to life-saving interventions [remains] inconsistent across the U.S." 6
These policy barriers have real-world consequences. As noted in a 2025 review, "access to life-saving interventions [remains] inconsistent across the U.S." 6 . This inconsistency disproportionately affects marginalized communities, with Black communities continuing "to face the highest overdose rates, yet drug-checking remains largely unavailable in our neighborhoods" 2 .
In contrast to the fragmented American approach, Europe has developed a more coordinated system through the TEDI network. This network collects standardized data from participating drug checking services across Europe and submits aggregated information to the European Union Drugs Agency (EUDA) 8 . This collaborative approach allows for better monitoring of transnational drug trends and facilitates a more coordinated public health response.
The TEDI network represents a mature model of how drug checking can be integrated into public health systems when supported by cooperative policy frameworks. Their work demonstrates the value of standardized data collection and cross-border cooperation in addressing a global challenge.
The field of drug checking continues to evolve with several promising developments:
Research like the NIST study points toward future test strips designed for subsequent laboratory analysis 9 .
Apps and digital platforms to share real-time drug alert warnings when dangerous batches are identified.
| Item | Function | Application Context |
|---|---|---|
| Methanol | Solvent for extracting compounds from test strips or drug samples | Laboratory analysis following initial screening 9 |
| Reference Standards | Pure chemical samples for comparison and calibration | Accurate identification of unknown substances in laboratory testing |
| Fentanyl Test Strips | Rapid detection of fentanyl and some analogues | Point-of-care use by service users and harm reduction programs 9 |
| FTIR Spectrometer | Identification of chemical components in a sample | Direct service provision at fixed sites or mobile units |
| Mass Spectrometer | Highly sensitive identification and quantification of substances | Confirmatory testing in laboratory settings 9 |
| Harm Reduction Cards | Standardized forms for collecting sample metadata | Gathering consistent data on drug market trends 2 |
Drug checking represents a pragmatic, science-based approach to reducing harm in an increasingly dangerous drug supply. While not a silver bullet for the overdose crisis, it provides a critical layer of protection for people who use drugs, offering them the information they need to make safer choices. The practice sits at the intersection of public health, analytical chemistry, and drug policy—a testament to the need for multidisciplinary solutions to complex problems.
As the drug supply continues to evolve with new synthetic compounds like nitazenes and medetomidine, the importance of drug checking will only grow 2 5 . The challenge for policymakers, public health officials, and society at large is to embrace these evidence-based interventions, remove the regulatory barriers that limit their effectiveness, and recognize that reducing harm is always a more compassionate—and often more effective—approach than mere punishment alone.
The future of drug checking will likely involve greater technological sophistication, but its core mission will remain the same: to provide people with potentially life-saving information about what they're consuming, without judgment, and to create a bridge between often-marginalized drug-using communities and the public health system. In a crisis that has claimed so many lives, such bridges have never been more necessary.
References will be added here manually.